DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial

Launched by FRED HUTCHINSON CANCER CENTER · Jul 1, 2024

Keywords

ClinConnect Summary

The DR. DREAM Trial is a research study looking at a new treatment called decoy-resistant interleukin-18 (DR-18) for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These are types of blood cancers that can come back after a patient has undergone a stem cell transplant, which is currently the only treatment that can potentially cure these conditions. The main goal of this trial is to find out if DR-18 is safe, what side effects it may cause, and how well it works in helping patients whose cancer has returned or has not improved after their transplant.

To be eligible for this study, participants must be at least 18 years old and have confirmed AML or MDS that has come back or did not get better after a stem cell transplant. They should also have shown no major complications related to the transplant in recent weeks and must have stable blood counts. If someone joins the trial, they will receive DR-18 and be closely monitored for any side effects and how their cancer responds. This trial is currently recruiting participants, and all individuals interested will need to provide informed consent and meet specific health criteria to ensure their safety during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years of age (no upper age limit)
• • Documented persistent or recurrent AML or MDS after HCT (including measurable residual disease \[MRD\] or overt leukemia). Nota bene (NB): MRD (\< 5% malignant blasts) must be detected with flow cytometry testing at University of Washington Medical Center (UWMC)/Fred Hutchinson Cancer Center (Fred Hutch) clinical laboratory
• • No Food and Drug Administration (FDA)-approved targeted therapy for the subject's AML or MDS is available, or if such therapy is available, that class of drugs previously failed for the subject or the subject was intolerant of the therapy
• • No history of grade 3 or 4 acute GvHD after the most recent HCT
• • No history of moderate or severe chronic GvHD after the most recent HCT
• • No active acute or chronic GvHD or other immunologic phenomenon (e.g., immune cytopenias, cryptogenic immunologic pneumonia) in last month requiring systemic therapy (Hydrocortisone or prednisone for adrenal insufficiency at ≤ 10 mg/day prednisone-equivalent is permitted.)
• • Stable or reducing immune suppression in the preceding 4 weeks without GvHD flares
• • The most recent HCT was from a 10/10 human leukocyte antigen (HLA)-matched related or unrelated donor (assessed at HLA-A, B, C, DR, DQ)
• • Evidence of blood count recovery at any time post-HCT defined as absolute neutrophil count (ANC) ≥ 0.5 x 10\^9/L for ≥ 3 consecutive days and platelets ≥ 30 x 10\^9/L (independent of granulocyte colony-stimulating factor \[G-CSF\] or platelet transfusions for 5 days). (Blood count recovery may not be sustained.)
• • No cellular immunotherapy or new targeted therapy in the 4 weeks prior to enrollment
• • Karnofsky performance status (KPS) ≥ 80%
• • Not pregnant/breastfeeding
• • Agrees to use a suitable method of contraception for 4 months after the last dose of DR-18
• • Capable of providing informed consent
• • At least 60 days have elapsed since the HCT donor cell infusion (HCT day 0). (There is no upper limit to the time elapsed since HCT.)
• Exclusion Criteria:
• • Active moderate-severe thrombotic microangiopathy (TMA) as evidenced by any of the following: \> 10 schistocytes per high-power field, or required anti-C5 or other anti-complement therapy for TMA in the prior 4 weeks, any of the following manifestations if attributed to TMA in the prior 4 weeks: hypertension, worsening or new renal insufficiency, ≥ 2+ proteinuria, hematochezia, seizure, transient or ongoing neurologic deficits
• • Renal insufficiency: Estimated glomerular filtration rate (eGFR) (calculated per the performing laboratory's standard formula) or measured 24 hour (hr.) creatinine clearance \< 30 mL/min
• • Hemodialysis in the prior 4 weeks
• • Major cardiac event requiring evaluation in the emergency room (ER) or hospitalization in the past 4 weeks
• • New York Heart Association (NYHA) class II or higher congestive heart failure (CHF) in the past 4 weeks
• • Uncontrolled cardiac arrhythmias, including atrial fibrillation
• • Left ventricular ejection fraction (LVEF) \< 35%. LVEF may be established with echocardiogram or MUGA scan, and left ejection fraction must be ≥ 35%
• • Liver dysfunction: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 5 x upper limit of normal (ULN) or bilirubin \> 3 x ULN
• * Active uncontrolled infection. NB: Examples of controlled infections:
• • Bacterial infection may be still requiring antibiotics at the time of enrollment, but clinical signs and symptoms of the infection should be improving. If the subject had bloodstream infection, negative blood cultures off antibiotics must be documented prior to initiating DR-18 treatment. For urinary tract infection, a repeat urine culture must be sterile prior to initiating DR-18. Radiographic improvement of bacterial pneumonia may lag behind clinical improvement so is not mandatory prior to DR-18 initiation
• • Fungal infection may be still requiring antifungal medication at the time of enrollment, but evidence of clinical response to antifungal medication (such as regression of lesions on chest CT) must be available at the time of enrollment
• • Asymptomatic shedding of respiratory viruses after cessation of antiviral therapy, or if not specifically treated with antiviral therapy, is permitted
• • Cytomegalovirus (CMV) viremia or organ infection meeting institutional criteria for CMV treatment with antiviral therapy such as ganciclovir, valganciclovir or foscarnet must be on maintenance phase of treatment or must have completed treatment and must not be in the induction treatment phase at the time of enrollment. Low-level CMV viremia not meeting institutional criteria for antiviral therapy is permitted, including low-level viremia in patients receiving CMV prophylaxis with letermovir
• • Any of the following: Pulmonary dysfunction requiring supplemental oxygen, even intermittently, in the past 2 weeks; corrected diffusion capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) \< 60% predicted; bronchiolitis obliterans syndrome; prior diagnosis of idiopathic pulmonary fibrosis; prior diagnosis of drug-induced pneumonitis; cryptogenic organizing pneumonia under active treatment
• • Seizure in the past 4 weeks or significant underlying neurologic disease: Study participants must not have significant active underlying neurologic disease, such as Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, prior symptomatic ischemic or hemorrhagic stroke, or transient ischemic attack, unless approved by principal investigator (PI). Peripheral neuropathy related to diabetes or prior chemotherapy is acceptable
• • Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI
• • Known allergic reactions to any of the components of study treatments
• • Concurrent use of other investigational anti-cancer agents
• • Peripheral blood T cell chimerism \< 40%